🇺🇸 HISTAMINE PHOSPHATE in United States

FDA authorised HISTAMINE PHOSPHATE on 25 April 1939 · 76 US adverse-event reports

Marketing authorisations

FDA — authorised 25 April 1939

  • Application: NDA000734
  • Marketing authorisation holder: LILLY
  • Local brand name: HISTAMINE PHOSPHATE
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. False Negative Investigation Result — 48 reports (63.16%)
  2. Anaphylactic Reaction — 7 reports (9.21%)
  3. Skin Test Positive — 4 reports (5.26%)
  4. Skin Wound — 4 reports (5.26%)
  5. Erythema — 3 reports (3.95%)
  6. Hypersensitivity — 2 reports (2.63%)
  7. Injection Site Pain — 2 reports (2.63%)
  8. Injection Site Ulcer — 2 reports (2.63%)
  9. Intentional Product Use Issue — 2 reports (2.63%)
  10. Tenderness — 2 reports (2.63%)

Source database →

HISTAMINE PHOSPHATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is HISTAMINE PHOSPHATE approved in United States?

Yes. FDA authorised it on 25 April 1939; FDA has authorised it.

Who is the marketing authorisation holder for HISTAMINE PHOSPHATE in United States?

LILLY holds the US marketing authorisation.